Clinical Trial Update: Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of MAGE-A3 + AS-15 in muscle-invasive bladder cancer post-cystectomy was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urinary Bladder Neoplasms

Drugs mentioned

• MAGE-A3 + AS-15 (MAGE-A3 + AS-15)

Snippet

Sponsor: European Association of Urology Research Foundation | Conditions: Urinary Bladder Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2019-01-09